Guriqbal “Guriq” S. Basi, Ph.D. has been appointed chief scientific officer, Sarepta Therapeutics, Inc. Dr. Basi brings 30 years of experience having held roles of increasing responsibility at Elan and other biotechnology companies. Dr. Basi will report to Douglas Ingram, Sarepta’s chief executive officer, and will be responsible for leading the direction of the company’s discovery pipeline and translational research efforts. 

Dr. Basi previously served as chief science and technology officer at Elan and head of preclinical development. He was also the former CSO for Circuit Therapeutics, Inc. and Symic Biomedical.

“Dr. Basi brings to Sarepta a long and impressive career marked by a commitment to scientific excellence,” said Mr. Ingram. “I am excited to bring Dr. Basi to the team as we focus on accelerating our pipeline. We have made strides toward our goal of bringing therapies and a better life to as many children with Duchenne muscular dystrophy as possible, but patients are waiting and we must accelerate our efforts. Dr. Basi’s expertise will prove invaluable as we move our next-generation technology into the clinic and continue to support and advance our exciting collaborative programs.”